

Oregon Prescription Drug Monitoring Program Advisory Commission

April 18, 2025 1:00 PM Meeting Minutes

Meeting Contact: Stephanie Vesik, Stephanie.g.vesik@oha.oregon.gov, 971-200-9463

Advisory Commission Attendees:

Laura Armstrong, OD, MEd, FAAO – Chair, Optometrist, representing the Board of Optometry and Oregon Optometric Physicians Association

John Hinton, DO, MPH – Physician, representing Osteopathic Physicians and Surgeons of Oregon

Maureen McAvoy Jemison – Public member with expertise in information technology

Dan Kennedy – Oregon State Pharmacy Association

Kaley Bourgeois, ND – Naturopathic physician representing the Oregon Association of Naturopathic Physicians

Lina Dorfmeister CRNA NSPM-c – Pain and addiction management clinic, Coos Bay, OR

Absent:

Tracy Klein - PhD, FNP, Representing Oregon Nurses Association

Katie Zinno – Public member and patient advocate, living with chronic diseases

OHA Staff Attendees:

Drew Simpson – Information Systems Manager

Stephanie Vesik– Program Coordinator

Tamara Ramirez – PDMP Operations and Coordination Specialist

Bryan Loy – Research Analyst, PDMP Data Stewardship

Ariane Erickson – Research Analyst, overseeing quarterly and annual metrics for PDMP.

Elizabeth McCarthy – Overdose Epidemiologist and PDMP Epidemiologist

Introductions

Meeting was called to order by Laura Armstrong.

PDMP staff and commission members introduced themselves, including new roles and tenure with the program.

Review of Previous Meeting's Minutes

Minutes from the previous meeting were reviewed and approved without changes.

Motion: Dan Kennedy

Second: John Hinton

Standing Agenda Items

a. Review quarterly metrics

Quarterly Report

Ariane Erickson presented Q4 2024 data to the Commission. Of note during the presentation included discussion on enrollment. 87% of all prescribers are enrolled in PDMP; 99% enrollment for top prescribers. Automated queries increased (76% usage), while web portal use decreased. Controlled substance prescriptions rose 5.4%; amphetamine became the top prescribed medication. Notably gabapentin moved from the top prescribed medication to second most, and opioids had mixed trends.

In system usage Ariane discussed that there had been consistent registration rates across prescribers. The number of active gateway-integrated facilities increased over the fourth quarter of 2024, and while gateway usage increased there was a decrease in web queries. There was some discussion over the type of requests for integration coming into the PDMP, the commission was advised that while the large facilities have already integrated, we now see mostly small and in independent clinics registered.

Laura Armstrong asked questions regarding registration practices of the PDMP, Stephanie Vesik discussed that registration efforts within the PDMP originally focused on those indicated as top prescribers within the state and PDMP staff traveled to clinics and conferences to focus on those providers. In recent years effort expanded to all prescribers in Oregon and the outreach conducted by the licensing boards. Registration of all prescribers in Oregon holding both licensure and DEA registration has remained static the past three years at about 87% and while the master list of prescribers required to register with the PDMP is dynamic.

Dashboard resources and stimulant-specific reports were highlighted.

Pharmacy Compliance

Stephanie Vesik shared updates on Q1 compliance efforts focusing on the new legislative mandates to collect schedule V controlled substances, veterinary data, and 'date sold'. Because of issues with the date sold our vendor Bamboo Health has changed their process of issuing warning that went into effect in April and there will be a full enforcement of "date sold" beginning in May.

Two major pharmacy chains had reporting issues regarding the 'date sold' field that resulted in large scale failures of dispensation reporting but resolved them within a week of finding the problem.

There have been no widespread issues of veterinary data being submitted by retail pharmacy locations. There has been one location having difficulty reporting to the PDMP, a Veterinary teaching hospital pharmacy facing challenges due to software incompatibility. PDMP staff are waiting on the complete record of Q1 2025 data to be available by the vendor to review for greater issues.

b. Research study updates

Bryan Loy summarized the 5 active Data Use Agreements (DUAs) and that 4 of the 5 have their data and are working through the analysis. The one DUA awaiting its data needs to submit a list of patients for Bryan to do the appropriate data linkage. He also shared to date there are 32 publications using PDMP data. He highlighted a 2024 study, utilizing OR PDMP data, on overdose risks among opioid-naive older adults. The study had findings included higher overdose risks associated with Medicaid enrollment, polypharmacy, and high initial MME doses.

c. Subcommittee Activities Update

Liz McCarthy presented prescribing practice trend data starting with a review of the five risky prescribing measures (co-prescribing, multiple prescribers, etc.). She discussed how the Tri-prescribing (opioid, stimulant, and sedative) measure introduced. Subcommittee exploring new trends, such as opioid pill quantity and patient age distribution.

d. Legislative Update

Drew Simpson reported only one bill with PDMP impact (tribal data sharing) is progressing. Other potential bills for future sessions may involve VA and military data sharing.

New Business

Discussion held on reducing meetings from four to two annually due to program maturity. Consensus to meet twice a year: January and October, third Friday at 1 PM. Motion passed unanimously. Quorum concerns and flexibility for ad hoc meetings were noted.

Open Issues

No Open issues were addressed during the meeting.

Public Comment

There were no members of the public in attendance.

Next Meeting Date: October 18th, 2024